𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants

✍ Scribed by Alfredo Marzano; Pietro Lampertico; Vincenzo Mazzaferro; Silvia Carenzi; Mauro Vigano; Raffaele Romito; Andrea Pulvirenti; Alessandro Franchello; Massimo Colombo; Mauro Salizzoni; Mario Rizzetto

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
118 KB
Volume
11
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prevention of hepatitis B recurrence aft
Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis
✍ Shusen Zheng; Yaomin Chen; Tingbo Liang; Anwei Lu; Weilin Wang; Yan Shen; Min Zh πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 109 KB πŸ‘ 1 views

The aim of our study was to determine the outcomes of liver transplant recipients receiving either lamivudine (LAM) monotherapy or LAM combined with low-dose intramuscular (IM) hepatitis B Immunoglobulin (HBIG) therapy. We performed a retrospective review of the medical records of patients that had

Role of long-term lamivudine treatment o
Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation
✍ Hyun Young Woo; Jong Young Choi; Jeong Won Jang; Chan Ran You; Si Hyun Bae; Seun πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 116 KB πŸ‘ 1 views

## Abstract In this study, the long‐term (>3 years) efficacy of combination therapy for hepatitis B virus (HBV) recurrence and the associated factors were investigated. One hundred and sixty‐five consecutive HBsAg‐positive patients (92 with liver cirrhosis, 73 with hepatocellular carcinoma; HCC) wh

Factors associated with viral breakthrou
Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation
✍ Henry Lik-Yuen Chan; Albert Ka-Keung Chui; Wan-Yee Lau; Francis Ka-Leung Chan; M πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 77 KB

This study aimed to investigate the factors associated with viral breakthrough among liver transplant recipients who receive lamivudine monoprophylaxis. Consecutive patients receiving liver transplantation for HBV-related liver disease from June 1999 to October 2000 were studied. All patients receiv

Lamivudine therapy in patients undergoin
Lamivudine therapy in patients undergoing liver transplantation for hepatitis b virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immu
✍ McCaughan, Geoffrey W. ;Spencer, Jenean ;Koorey, David ;Bowden, Scott ;Bartholom πŸ“‚ Article πŸ“… 1999 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 75 KB πŸ‘ 1 views

Recurrent hepatitis B virus (HBV) infection remains a major cause of morbidity and mortality after liver transplantation. Recently, antiviral therapy, such as lamivudine, has become available for prophylaxis against HBV reactivation posttransplantation and for the treatment of HBV recurrent disease.

Lamivudine prophylaxis reduces the incid
Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma
✍ Yu-Hong Li; Yi-Fu He; Wen-Qi Jiang; Fen-Hua Wang; Xu-Bin Lin; Li Zhang; Zhong-Ju πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 81 KB

## Abstract ## BACKGROUND Hepatitis B virus (HBV) infection is a common disease in China. Severe hepatitis is a well recognized complication in HBV carriers with malignant disease who receive cytotoxic chemotherapy. The objective of the current study was to assess the value of antiviral lamivudine